61098-38-2

Basic information

• Product Name: 5,7-dichloro-6-methylpyrazolo[1,5-a]pyrimidine
• Synonyms: 5,7-dichloro-6-methylpyrazolo[1,5-a]pyrimidine
• CAS NO: 61098-38-2
• Molecular Formula: C₇H₅Cl₂N₃
• Molecular Weight: 202.0407
• Mol File: 61098-38-2.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5,7-dichloro-6-methylpyrazolo[1,5-a]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5,7-dichloro-6-methylpyrazolo[1,5-a]pyrimidine(61098-38-2)
• EPA Substance Registry System: 5,7-dichloro-6-methylpyrazolo[1,5-a]pyrimidine(61098-38-2)

Safety Data

• Hazardous Substances Data: 61098-38-2(Hazardous Substances Data)

Usage

General Description

5,7-dichloro-6-methylpyrazolo[1,5-a]pyrimidine is a chemical compound with a molecular formula C6H3Cl2N3. It is a derivative of pyrazolo[1,5-a]pyrimidine and is characterized by the presence of two chlorine atoms and a methyl group on the pyrazole ring. 5,7-dichloro-6-methylpyrazolo[1,5-a]pyrimidine has been studied for its potential use in the development of pharmaceuticals and agrochemicals, as well as in research applications. Its unique structure and potential biological activities make it a molecule of interest for further investigation in the field of medicinal chemistry and drug discovery.

Upstream product

• 1820-80-0 3-aminopyrazole 
• 609-08-5 Diethyl methylmalonate 
• 57489-71-1 6-methylpyrazolo[1,5-a]pyrimidine-5,7-diol 
• 10025-87-3 trichlorophosphate 

Downstream Products

• 1273190-06-9 3-chloro-4-(7-(cyclopropylamino)-3-formyl-6-methylpyrazolo[1,5-a]pyrimidin-5-ylamino)benzonitrile 
• 1273190-08-1 5-(4-(1H-pyrazol-1-yl)phenylamino)-7-(cyclopropylamino)-6-methylpyrazolo[1,5-a]pyrimidine-3-carbaldehyde 
• 1393882-31-9 ethyl 3-({5-chloro-6-methylpyrazolo[1,5-a]pyrimidin-7-yl}amino)benzoate 
• 1393882-32-0 N-[3-(benzyloxy)phenyl]-5-chloro-6-methylpyrazolo[1,5-a]pyrimidin-7-amine 
• 876391-36-5 5-chloro-N-(4-ethoxyphenyl)-6-methylpyrazolo[1,5-a]pyrimidin-7-amine 
• 754205-53-3 ethyl-3-({5-[(trans-4-aminocyclohexyl)amino]-6-methylpyrazolo[1,5-a]pyrimidin-7-yl}amino)benzoate 
• 754207-57-3 5-N-(trans-4-aminocyclohexyl)-7-N-[3-(benzyloxy)phenyl]-6-methylpyrazolo[1,5-a]pyrimidine-5,7-diamine 
• 754204-72-3 5-N-(4-aminocyclohexyl)-7-N-(2-chlorophenyl)-6-methylpyrazolo[1,5-a]pyrimidine-5,7-diamine 
• 1393882-56-8 tert-butyl (S)-3-[(7-{[(tert-butoxy)carbonyl](4-ethoxyphenyl)amino}-6-methylpyrazolo[1,5-a]pyrimidin-5-yl)amino]piperidine-1-carboxylate 
• 1393882-00-2 tert-butyl (S)-3-[(7-{[4-(benzyloxy)phenyl][(tert-butoxy)carbonyl]amino}-6-methylpyrazolo[1,5-a]pyrimidin-5-yl)amino]piperidine-1-carboxylate 

Relevant articles and documents

MACROCYCLIC RIP2-KINASE INHIBITORS

The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2-kinase, and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.

Pyrazolopyrimidin CK2 and related heterocyclic compound as an inhibitor

The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and have the following general formula:

Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) as an antiinflammatory target: Discovery and in vivo activity of selective pyrazolo[1,5- a ]pyrimidine inhibitors using a focused library and structure-based optimization approach

A novel class of mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) inhibitors was discovered through screening a kinase-focused library. A homology model of MAPKAP-K2 was generated and used to guide the initial SAR studies and to rationalize the observed selectivity over CDK2. An X-ray crystal structure of a compound from the active series bound to crystalline MAPKAP-K2 confirmed the predicted binding mode. This has enabled the discovery of a series of pyrazolo[1,5-a]pyrimidine derivatives showing good in vitro cellular potency as anti-TNF-α agents and in vivo efficacy in a mouse model of endotoxin shock.